You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

CLINICAL TRIALS PROFILE FOR ENTINOSTAT

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for Entinostat

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00015925 ↗	MS-275 in Treating Patients With Hematologic Cancer	Completed	National Cancer Institute (NCI)	Phase 1	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of MS-275 in treating patients who have hematologic cancer.
NCT00015925 ↗	MS-275 in Treating Patients With Hematologic Cancer	Completed	Sidney Kimmel Comprehensive Cancer Center	Phase 1	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of MS-275 in treating patients who have hematologic cancer.
NCT00015925 ↗	MS-275 in Treating Patients With Hematologic Cancer	Completed	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 1	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of MS-275 in treating patients who have hematologic cancer.
NCT00020579 ↗	MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma	Completed	National Cancer Institute (NCI)	Phase 1	RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid tumors or lymphoma.
NCT00020579 ↗	MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma	Completed	National Institutes of Health Clinical Center (CC)	Phase 1	RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid tumors or lymphoma.
NCT00098891 ↗	MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas	Completed	National Cancer Institute (NCI)	Phase 1	Phase I trial to study the effectiveness of combining MS-275 with isotretinoin in treating patients who have metastatic or advanced solid tumors or lymphomas. MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Isotretinoin may help cancer cells develop into normal cells. MS-275 may increase the effectiveness of isotretinoin by making cancer cells more sensitive to the drug. MS-275 and isotretinoin may also stop the growth of solid tumors or lymphomas by stopping blood flow to the cancer. Combining MS-275 with isotretinoin may kill more cancer cells
NCT00101179 ↗	MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia	Completed	National Cancer Institute (NCI)	Phase 1	MS-275 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving MS-275 together with azacitidine may kill more cancer cells. This phase I trial is studying the side effects and best dose of MS-275 when given together with azacitidine in treating patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for Entinostat

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Breast Cancer	10
Recurrent Adult Acute Myeloid Leukemia	5
Chronic Myelomonocytic Leukemia	4
Secondary Acute Myeloid Leukemia	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Breast Neoplasms	20
Carcinoma	13
Lung Neoplasms	11
Carcinoma, Non-Small-Cell Lung	11
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Entinostat

Trials by Country

Map
Table

Trials by Country
Location	Trials
United States	331
Japan	15
China	5
Georgia	3
Australia	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
Maryland	32
California	18
New York	16
Texas	15
Pennsylvania	15
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Entinostat

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	24
Phase 1/Phase 2	15
[disabled in preview]	29
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	26
Active, not recruiting	13
Terminated	9
[disabled in preview]	20
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Entinostat

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
National Cancer Institute (NCI)	30
Syndax Pharmaceuticals	27
Merck Sharp & Dohme Corp.	4
[disabled in preview]	12
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Industry	52
Other	37
NIH	31
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.